Resother Pharma initiates First in Human studies with RTP-026

ResoTher Pharma today announced that the company has received approval to initiate human clinical development with RTP-026, the company’s lead peptide drug candidate.The phase I trial will be conducted at a clinical site in Liege, Belgium where intravenous infusion of...

ResoTher Pharma appoints Samra Sanni as VP of Research

ResoTher Pharma is pleased to announce the appointment of Samra Sanni, PhD, as Vice President, Drug Research as of today September 15th 2021. Samra will be responsible for preclinical drug research and development of novel drug molecules.  Samra has a successful track...

ResoTher Pharma appoints Teis Vester as Chief Financial Officer

ResoTher Pharma is pleased to announce the appointment of Teis Vester, MSc., as Chief Financial Officer as of today, August 16th, 2021. Teis will report to Lone Veng, CEO, and replaces co-founder Jeppe Øvlesen, who remains in the company as a member of the Board of...

ResoTher Pharma strengthens its leadership team

ResoTher Pharma is pleased to announce the following changes to its leadership team to further support the growth and development of the company. Teis Vester, MSc., will take on the role of Chief Financial Officer from August 16th, 2021, replacing co-founder Jeppe...

ResoTher Pharma announces changes to its Board of Directors

ResoTher Pharma ApS, Holte, Denmark, announces today that the shareholders has elected two new members to the company’s Board of Directors at the Annual General Meeting held May 31st, 2021. Thomas Feldhus, MBA, a Copenhagen-based life science executive joins the...

ResoTher Pharma announces capital raise of DKK 38.8M

Press release: ResoTher Pharma ApS, a Danish biotech company, today announces the successful completion of a new share issue. The transaction was completed with share subscriptions from existing and new investors in collaboration with North Finance A/S, a Danish...